Synbio International Appoints Dr. Nick Vatakis as Medical Director

Synbio International Inc. has announced a significant enhancement to its leadership team with the appointment of Dr. Nick Vatakis as Medical Director. This decision, revealed on October 22, 2025, underscores the company’s dedication to advancing its AI-driven facial analysis technology aimed at screening for depression.

Dr. Vatakis brings nearly three decades of expertise in psychiatry and clinical research. He is a notable figure in the field, having served as principal investigator for over 200 clinical trials that encompass various psychiatric and neurological conditions. His extensive background in psychopharmacology and integrative multimodal psychotherapy positions him as a key asset for Synbio as it seeks to validate and commercialize its innovative medical technology.

Leadership and Innovations

The company’s CEO, Claudio Solitario, expressed enthusiasm about Dr. Vatakis joining the team. “We are privileged to welcome Nick to Synbio’s leadership team. His vast experience in clinical research and psychiatry not only strengthens the integrity of our feasibility trial but also enhances our credibility with regulators, partners, and investors alike,” Solitario stated.

Dr. Vatakis will oversee the design and execution of the upcoming feasibility trial for the facial analysis depression screening software, ensuring adherence to the highest ethical, medical, and scientific standards. His role is critical as the company prepares to launch this important trial, which aims to demonstrate the effectiveness of its AI-assisted diagnostic tool.

The integration of Dr. Vatakis into the Board of Directors marks a pivotal step in Synbio’s journey toward clinical validation. His previous experience includes advising on numerous drug development programs and founding a clinical research organization in Eastern Europe. This blend of clinical knowledge and business acumen will be vital as Synbio navigates the complexities of bringing its technology to market.

About Synbio International Inc.

Founded with a mission to enhance medical diagnostics through innovative technology, Synbio International Inc. specializes in AI-driven solutions that bridge the gap between wellness and medicine. The company is committed to developing science-based applications that improve quality of life while empowering healthcare providers.

For further inquiries, media representatives can contact Synbio International Inc. via email at [email protected] or by phone at (646) 359-4854. More information can be found on their website at www.synbiointl.com.

As Synbio moves forward, the appointment of Dr. Vatakis signals a strategic enhancement to its leadership, reinforcing its commitment to scientific rigor and the advancement of mental health diagnostics.